The effect of Fenofibrate on the Clinical Outcome of primary Sclerosing Cholangitis

Shahid Beheshti University of Medical Sciences0 个研究点目标入组 30 人开始时间: 待定最近更新: 2022年2月7日

试验速览

暂无简介。

•chronic cholestatic liver disease for atleast 6 month
•alkaline phosphatase serum level atleast 1.5x upper limit normal
•multi focal dilation and stricture in intra/extra hepatic billiary ducts on MRCP or liver biopsy confirmed PSC (fibrosing cholangitis, ductopenia, peei portal inflammation or biliary fibrosis)

•concurrent advanced malignancy or severe cardiopulmonary disease with less than 2 years survival
•inlammatory intestinal diseasethat need medical therapy during 3 month from begining (except miantenance therapy with 5-ASA)
•candidate for liver transplant and survival less than 80% in 2 years according to MAYO risk score
•portal hypertension complicatin such as variceal bleeding ascitis liver encephalopathy
•pregnancy or breast feeding
•age under 18 years or above 75 years
•other liver disease diagonosis sucg as chronic alcoholic livera disease, B or C hepatitis, auto immune hepatitis, primary biliary cirrosis, hemochromatosis, wilson disease, congenital biliary disease or cholangiocarcinoma
•previous biliary stone or ductal manipulation, cholecycstectomy or other biliary drainage before PSC confirmed
•ascending biliary cholangitis need more than twice a years admission
•patient who di not allow
•fenofibrate allergy or intolerance or side effects
•concurrent use of local or systemic anti-itch agents such as anti histamins

发起方